Health Economics and Antimicrobial Stewardship
Reduce healthcare costs, improve quality measures, and shorten sepsis-related length of stay.
Economic Impact of Cytophenix FloCAST™
Reduce Sepsis-Related Length of Stay (LOS)
Reduce sepsis-related LOS and attendant costs of ICU or med/surg beds from 2–5 days per patient with faster time to effective therapy (TTET). ($36,655 – $42,895). (Wozniak et al.)8 (Ohsfeldt et al.)9 (Humphries et al.)10
Address MDR Candida Infections
Reduce LOS from MDR Candida spp. infections, including from Candida auris, showing 134% CAGR incidence in US hospital-acquired bloodstream infections, and additional cost of inpatient care ($25,207–$55,001). (CDC)11 (Yu et al.)12
Reduce Acuity of Care Costs
Reduce acuity of care costs for patients in ICU settings with faster TTET ($304,722). (AHA / US CDC)13
Improve Hospital-Acquired Condition Reduction Program (HACRP) Scores
Faster time to optimal therapy (TTOT) enabled by fast AST results may improve HAC Reduction Program scores with reduced incidence of C. difficile infection (CDI), faster discharges, and fewer U-turns (readmissions within 30-day window from last discharge). Average additional cost of hospital-onset CDI ($21,792 - $42,316). (Sahrmann et al.)14
Reduce Secondary Infection Risk
Faster TTOT can minimize disruption to the patient's balance of gut microbiota from extended broad-spectrum antimicrobial therapy. Reducing this disruption may lead to a reduced risk of secondary infections such as CDI that harm patients and increase CDI-associated cost of care (90% CL $21,152 – $21,744). (Zhang et al.)15
References
- Wozniak et al. PMID: 35832237.
- Ohsfeldt et al. 2021. PMID: 34609704.
- Humphries et al. 2019. PMID: 30690541.
- CDC, Tracking C. auris. Retrieved 5 March 2026.
- Yu et al. 2023, "Characteristics, costs, and outcomes associated with central-line–associated bloodstream infection and hospital-onset bacteremia and fungemia in US hospitals." PMID: 37424226.
- American Hospitals Association, US CDC.
- Sahrmann et al. 2022, "Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset." PMID: 36285546.
- Zhang et al. 2016. "Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study."
